Glanbia plc heads into its May 13 interim update with short-side activity unusually quiet — but a strong dividend score and improving EPS momentum make the forward earnings date the clearest near-term focal point.
The most notable thing about Glanbia's positioning right now is how little is happening on the short side. Exchange-reported short interest of 250 shares (as of the April 15 settlement date) translates to a negligible fraction of the float — this is not a stock that short sellers are pursuing with any conviction. The OTC ADR lending pool reflects that: availability has loosened almost entirely from what was a tighter picture in early March, when 50% utilisation was briefly recorded. That has since dropped to zero. Borrow cost data available to late February showed a rate of 6.3%, elevated relative to the stock's long-run norm but stale enough that the exact level warrants caution; there is no active pressure visible in the lending market today.
The forward earnings outlook, however, is where the constructive case gathers some weight. The 12-month forward EPS growth estimate ranks in the 98th percentile of the broader universe — a particularly strong signal for a mature packaged-foods name. EPS momentum scores of 64 (30-day) and 63 (90-day) confirm the direction of travel: analysts have been nudging estimates higher with some consistency. The dividend score ranks in the 91st percentile, consistent with Glanbia's profile as a steady cash returner — though the last declared dividend on record was from early 2022 (for the OTC ADR), meaning investors tracking income through this listing should verify the current dividend policy directly. The short score of 45, sitting in the 90th percentile for low short risk, reinforces the picture of a stock where bearish conviction is structurally absent.
Fundamentals frame a business of genuine scale, with estimated revenue approaching $4.1 billion, EBITDA of approximately $524 million, and an enterprise value near $5.6 billion. That implies an EV/EBITDA of roughly 10.8x — undemanding for a consumer staples franchise with this earnings momentum profile. Operating cash flow of $465 million against capex of $108 million leaves solid free cash flow generation, and net debt of $505 million looks manageable at just under one turn of EBITDA. The EV/EBIT multiple of ~14.9x also appears reasonable given the quality of cash generation.
Institutional ownership anchors the shareholder base with some stability. Glanbia Co-operative Society holds 18.1% as the dominant strategic anchor. Among financial institutions, Vanguard added 562,000 shares to reach 3.4% as of late March, while JP Morgan Asset Management lifted its position by 501,000 shares over the same quarter. Southeastern Asset Management made the sharpest relative move, adding 1.1 million shares to reach 0.79% by year-end 2025. These are incremental adds from names that tend to run concentrated, long-horizon books — the direction of flow is quiet but consistently positive.
The stock's last traded price on the OTC market was $102.21, recorded on April 10 — the ADR is thinly traded and the price data carries a 20-day lag. Investors tracking Glanbia's real-time performance are better served by the primary listing. What to watch on May 13 is whether management provides any colour on the trajectory of the performance nutrition division, where input cost pressures and consumer spending trends in the US remain the primary swing factors for the year.
See the live data behind this article on ORTEX.
Open GLAP.Y on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
